A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the safety and efficacy of JNJ-28431754 in nondiabetic overweight and obese subjects.

Trial Profile

A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the safety and efficacy of JNJ-28431754 in nondiabetic overweight and obese subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2013

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Obesity; Overweight
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 13 Nov 2013 Results published in Obesity (Silver Spring, Md.).
    • 29 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Jan 2009 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top